COMMUNIQUÉS West-GlobeNewswire

-
Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025
21/07/2025 -
George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US
21/07/2025 -
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
21/07/2025 -
Kraig Biocraft Laboratories Successfully Completes Lab-to-Field Transition for Three New Spider Silk Production Strains
21/07/2025 -
National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population
21/07/2025 -
ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia
21/07/2025 -
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
21/07/2025 -
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
21/07/2025 -
SAB BIO Announces Oversubscribed $175 Million Private Placement
21/07/2025 -
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
21/07/2025 -
Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary
21/07/2025 -
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease
21/07/2025 -
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
21/07/2025 -
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
21/07/2025 -
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
21/07/2025 -
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
21/07/2025 -
ProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury Initiative
21/07/2025 -
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
21/07/2025 -
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
21/07/2025
Pages